RxDoctor Payments Data

Daniel Plotnick, MD

Cardiovascular Disease · Towson, MDNPI 1356486039

Payments from drug & device makers

$13,648in general payments, 2019–2025

Across 645 payments — averaging $21.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Johnson & Johnson$993
  • Boehringer Ingelheim$970
  • Medtronic$933
  • Edwards Lifesciences$784
  • plus $7K from 35 others

What the payments were for

  • Consulting fees$190%
  • Food & beverage$13,606100%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,648 in reported general payments places this provider in the 80th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$299,564
Medicare patients
1,693
Services billed
4,935

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban497$640,532
XareltoRivaroxaban99$121,609
EntrestoSacubitril/Valsartan54$72,343
JardianceEmpagliflozin49$60,033
Repatha SureclickEvolocumab34$37,239
BrilintaTicagrelor31$31,547
MultaqDronedarone Hcl20$27,263
Praluent PenAlirocumab21$13,471
Repatha SyringeEvolocumab15$12,844
Atorvastatin Calcium519$7,449
Metoprolol Succinate426$7,248
Icosapent Ethyl16$6,376
Ezetimibe155$5,933
Rosuvastatin Calcium194$4,032
Carvedilol200$3,224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,406$640,532497 claims
Johnson & JohnsonXarelto$993$121,60999 claims
NovartisEntresto$755$72,34354 claims
Boehringer IngelheimJardiance$970$60,03349 claims
AstraZenecaBrilinta$698$31,54731 claims
Sanofi-aventis U.S. LLCMultaq$405$27,26320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Towson

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →